HBW Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
DM
HBW Advisory Services's CPRX Position: Q2 2023 in Review
HBW Advisory Services sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 12,949 shares — an estimated $215K sold.
HBW Advisory Services first reported a position in CPRX in Q4 2022 and held it in 2 quarters. The position peaked at $225K in Q4 2022. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.
- HBW Advisory Services reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
- HBW Advisory Services sold 12,949 Catalyst Pharmaceutical shares in Q2 2023, an estimated $215K.
- HBW Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 2 quarters.
- HBW Advisory Services's Catalyst Pharmaceutical position peaked at $225K in Q4 2022.
- 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.
Based on HBW Advisory Services's 13F filing for Q2 2023, filed 6 Jul 2023.